Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Seizures × enzalutamide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 149 Neoplasm Metastasis 18 Breast Neoplasms 18 Prostatic Neoplasms, Castration-Resistant 16 Neoplasms 14 Prostate Cancer Metastatic 7 Metastatic Castration-Resistant Prostate Cancer 7 Metastatic Castration Resistant Prostate Cancer 7 Triple Negative Breast Neoplasms 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Pancreatic Neoplasms 4 Metastatic Castration-resistant Prostate Cancer 4 Melanoma 4 Carcinoma, Non-Small-Cell Lung 4 Squamous Cell Carcinoma of Head and Neck 3 Small Cell Lung Carcinoma 3 Prostate Adenocarcinoma 3 Colorectal Neoplasms 3 Carcinoma, Hepatocellular 3 Adenocarcinoma 3 mCRPC 2 Uterine Cervical Neoplasms 2 Urinary Bladder Neoplasms 2 Recurrence 2 Ovarian Neoplasms 2 Metastatic Hormone Sensitive Prostate Cancer 2 Metastatic Castration-Resistant Prostate Cancer (mCRPC) 2 Lymphoma, Non-Hodgkin 2 Endometrial Neoplasms 2 Castration-resistant Prostate Cancer 2

Interventions

Levetiracetam 6 perampanel 2 Cannabidiol 2 enzalutamide 1 Tranexamic Acid 1 Standard of Care 1 Sodium Chloride 1 Saline Solution 1 Pregabalin 1 Medical Marijuana 1 Magnesium Sulfate 1 Everolimus 1 Curcumin 1 Cholecalciferol 1 Aspirin 1 Anticonvulsants 1 Anastrozole 1 2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01977651 2024-12-06

UPWARD

Astellas Pharma Inc

Phase 4 Completed

424 enrolled 10 charts

Seizures

Data powered by HemOnc (CC BY 4.0) Colophon ⚡